---
aliases: 
tags:
  - Class/Permanent-Note
  - Topic/-
---




# AI Summary

# Hepatic & HPB Quick-Reference Study Guide (MD1)

> Integrated summary of **three lectures**: 
> - [[08.1.8 Medical liver disease (Pathology)|medical liver conditions (pathology)]], 
> - [[09.4.2 Hepatopancreatobiliary tumours (Pathology)|hepatopancreatobiliary (HPB) tumours (pathology)]]
> - [[09.3.3 Drugs in liver disease (Pharmacology)|drugs in liver disease (clinical pharmacology)]]
> 
> Detail scales with slide emphasis.

---

## Global High-Yield Concepts (read this first)

* **Three histologic patterns** underpin most liver disease: **hepatitis (inflammation), steatosis, cholestasis**. Many conditions show overlap.&#x20;
* **Cirrhosis** (scarring, portal hypertension) drives shunting, altered enzyme activity, and protein binding → **broad PK/PD changes** and prescribing risk.&#x20;
* **High vs low hepatic extraction** drugs behave differently with reduced hepatic blood flow vs reduced enzyme capacity; **first-pass** changes matter.&#x20;
* HPB tumour taxonomy: liver (HCC, cholangiocarcinoma, adenoma, metastases), pancreas (PDAC, cystic neoplasms, Pan-NEN). Know **diagnosis, spread, and management basics**.&#x20;

---

# A. Medical Liver Conditions (non-neoplastic)

## Hepatitis (Acute & Chronic) — **High detail**

**Definition & pattern**

* Necro-inflammatory process with portal ± lobular injury, **interface hepatitis**, apoptosis/coagulative necrosis, and repair → fibrosis/cirrhosis.&#x20;

**Acute (≤6 mo):** fatigue, anorexia, RUQ tenderness, jaundice; usually 2–4 wk course; minority → acute liver failure. Causes include **HAV/HEV (majority), HBV/HCV/HDV, drugs (e.g., paracetamol), toxins, ischaemia, pregnancy, autoimmune, metabolic (Wilson)**, others. &#x20;

**Chronic (>6 mo):** often asymptomatic; leads to cirrhosis/carcinoma depending on aetiology. Causes: **HBV/HCV, alcohol, drugs (methotrexate, amiodarone, isoniazid), AIH, PBC/PSC, A1AT, haemochromatosis, Wilson, MAFLD**.&#x20;

**Biopsy pearls:** portal inflammation cell mix, **interface hepatitis**, lobular activity; clinicopath correlation required.&#x20;

**Classic patterns (exam-facing):**

* **HBV:** ground-glass hepatocytes (HBsAg).&#x20;
* **HCV:** low-grade hepatitis with **lymphoid aggregates** ± steatosis.&#x20;
* **AIH:** interface hepatitis, **plasma cells**, hepatocyte **rosettes**.&#x20;
* **Drug hypersensitivity:** **eosinophils** may be prominent.&#x20;

**Investigations (core set):** LFT pattern (AST/ALT vs ALP/GGT), bilirubin, **synthetic function (albumin, PT/INR)**, viral serology/PCR, autoimmune serology (ANA, SMA, AMA), iron studies, imaging, biopsy when needed.&#x20;

---

## Metabolic-Associated Fatty Liver Disease (MAFLD/MASLD & MASH) — **High detail**

**Associations:** obesity, diabetes, metabolic syndrome, prior GI surgery, TPN.&#x20;

**Histology:** **macrovesicular fat**, ballooned hepatocytes, **Mallory–Denk bodies**, lobular inflammation, sinusoidal/pericellular fibrosis (progression risk). &#x20;

**Differentials/overlap:** alcohol, drugs (methotrexate, amiodarone), HCV.&#x20;

---

## Alcohol-Related Liver Disease — **Moderate detail**

**Spectrum:** steatosis ↔ alcoholic hepatitis (neutrophils, **Mallory’s hyaline**) ↔ fibrosis/cirrhosis; central vein sclerosis; mild iron.&#x20;

**Path features to recall:** **Mallory’s hyaline**, neutrophilic satellitosis.&#x20;

---

## Drug-Induced Liver Injury (DILI) — **Moderate detail**

* Culprits across patterns (steatosis: **methotrexate, amiodarone**; cholestasis: **flucloxacillin**), hypersensitivity with **eosinophils**. &#x20;
* **Paracetamol**: key acute hepatotoxin (see dosing cautions in cirrhosis below).&#x20;

---

## Cholestasis (Syndromic Pattern) — **High detail**

**General histology:** feathery degeneration, **bile plugs**, ductular reaction, inflammation, fibrosis → cirrhosis.&#x20;

**Mechanistic buckets:**

* **Pre-hepatic** (excess bilirubin production).
* **Intrahepatic** (PBC, PSC, drugs, inborn errors).
* **Post-hepatic** (extra-hepatic obstruction: gallstones, pancreatic head tumours) with **bile lakes** ± ascending cholangitis/abscess.&#x20;

---

### Primary Biliary Cholangitis (PBC) — **High detail**

* **Autoimmune small-duct** cholestatic disease: **duct damage**, portal inflammation ± **granulomas**; progressive **duct loss**, interface hepatitis, fibrosis → cirrhosis (4 stages). **AMA positive** serology is typical.  &#x20;

---

### Primary Sclerosing Cholangitis (PSC) — **High detail**

* **Largeor small-duct** cholangiopathy: **concentric (“onion-skin”) periductal fibrosis**, inflammation → duct loss; cholestatic labs/imaging.&#x20;

---

### Extra-Hepatic Biliary Obstruction (EHBO) — **Moderate detail**

* **Causes:** gallstones, **pancreatic head tumours**.
* **Pathology:** ductal bile plugs, bile lakes/rupture, **ascending cholangitis** (neutrophils), abscesses.&#x20;

---

## Cirrhosis — **Moderate–High detail**

* End-stage scarring with **portal hypertension**; common sequel of chronic hepatitis, cholestatic disease, MAFLD, alcohol, metabolic diseases.&#x20;
* Staging/assessment uses **Child-Pugh, MELD**; these **poorly predict metabolic (drug) capacity**, and **shunting** isn’t directly measurable.&#x20;

---

## Acute Liver Failure — **Brief**

* Rapid loss of liver function (often severe acute hepatitis/DILI); minority of acute hepatitis cases progress.&#x20;

---

## Inherited/Metabolic Liver Diseases — **Moderate detail (grouped)**

* **Hereditary haemochromatosis:** iron overload; **iron granules** on stain. &#x20;
* **Wilson disease:** copper accumulation (listed under metabolic causes).&#x20;
* **Alpha-1 antitrypsin deficiency:** abnormal A1AT; typical inclusions.&#x20;
* **Cystic fibrosis-related liver disease:** included among metabolic/inborn errors.&#x20;

---

# B. Hepatobiliary & Pancreatic Tumours

## Hepatocellular Carcinoma (HCC) — **High detail**

**Epidemiology & risks:** Highest incidence in Asia; strongly linked to **HBV/HCV, alcohol, aflatoxin, haemochromatosis**; in West, usually on **cirrhosis**.&#x20;

**Gross/micro:** single/multifocal/diffuse; pale masses; **vascular invasion** with satellite nodules. Microscopy shows malignant hepatocytes in **thick plates**, acinar/solid patterns; **fibrolamellar** variant in young; mixed HCC-CC exists. &#x20;

**Diagnosis & Management:** imaging ± core/FNA; **resection**, **transplant (in chronic liver disease)**, **TACE**, chemo-radiation, targeted therapies.&#x20;

---

## Cholangiocarcinoma — **High detail**

* **Biliary epithelium malignancy** (intra/extrahepatic); associations: **PSC**, congenital disorders (e.g., **Caroli**), **liver flukes** (SE Asia). Path: **desmoplastic adenocarcinoma**, tends to **track portal tracts** and invade vessels; metastases to lung/bone/brain; mixed **cholangio-hepatocellular** variants occur.&#x20;

---

## Hepatic Metastases — **Moderate detail**

* **Most common malignant liver tumours**, often **multiple**; from **GI**, breast, lung, and many others.&#x20;

---

## Hepatocellular Adenoma (HCA) — **Moderate–High detail**

* **Young women; oral contraceptives**; complications: **subcapsular rupture/haemorrhage**; **rare progression to HCC** (subtype-dependent). Morphology: **well-demarcated**, sheets of hepatocytes, **no portal tracts**, **prominent arteries/veins**. &#x20;

* **Molecular subtypes** (H-HCA, IHCA, β-catenin HCA/b-IHCA) with characteristic **immunomarkers** and **variable HCC risk** (β-catenin exon 3 = high risk). **All**: haemorrhage risk if >5 cm.&#x20;

---

## Hepatoblastoma — **Brief**

* **Commonest primary liver tumour in children** (recognise name/age).&#x20;

---

## Pancreatic Ductal Adenocarcinoma (PDAC) — **High detail**

**Epidemiology:** Among top causes of cancer death; **late presentation**; poor 5-y survival; age >65.&#x20;

**Risks/precursors:** **Smoking (2–3×)**, new-onset diabetes, **chronic pancreatitis**, family history; **PanIN** dysplasia precedes carcinoma. &#x20;

**Pathology & spread:** gland-forming **adenocarcinoma**, perineural spread, early nodes, hematogenous **to liver**. &#x20;

**Treatment:** **Whipple** (head) or distal pancreatectomy (body/tail), chemo-radiation, targeted/immunotherapy.&#x20;

---

## Pancreatic Cystic Neoplasms (MCN, IPMN, IOPN) — **High detail**

* **Non-invasive** cystic tumours graded low–high; **excellent prognosis if no invasion**; if invasive, still **better than de-novo PDAC**. Surgical resection for high-risk/high-grade lesions (Whipple vs distal based on site). &#x20;

---

## Pancreatic Neuroendocrine Neoplasms (Pan-NEN) — **Moderate–High detail**

* From **islets** (tail common). All malignant potential: **well-differentiated NET (G1–G3)** vs **poorly differentiated NEC**.&#x20;

**Diagnosis work-up (service awareness):** **EUS-guided FNA/FNB**, ROSE cytology, specialised needles; multidisciplinary team.&#x20;

---

# C. Drugs in Liver Disease (clinical pharmacology)

## Prescribing in Cirrhosis — **High detail**

**Why tricky:** **Shunting** (↓ first-pass & hepatic flow), **variable enzyme down-regulation**, **↓ albumin** (↑ free drug), **ascites** (↑ Vd), **biliary/excretory changes**, and **altered PD** (e.g., CNS sensitivity, fragile coagulation). &#x20;

**Extraction ratio principle:**

* **High extraction (flow-limited)**: markedly affected by ↓ hepatic blood flow/shunting → ↑ bioavailability & exposure (e.g., **most β-blockers except atenolol, CCBs, nitrates, opiates, lignocaine, naloxone**).&#x20;
* **Low extraction (capacity-limited)**: more sensitive to ↓ enzyme activity/↓ protein binding (e.g., **warfarin, benzodiazepines, anticonvulsants, NSAIDs, theophylline, amiodarone**).&#x20;

**Clinical corollaries (know examples):**

* **Diazepam** (low extraction) → **↓ clearance & ↑ t½** in cirrhosis; **prefer lorazepam** (glucuronidation).&#x20;
* **Naloxone**/oxycodone combos: cirrhotic **shunting** can increase naloxone bioavailability → **reduced analgesia**.&#x20;
* **Verapamil** (high extraction + hepatic metabolism): oral bioavailability ↑ (≈20%→≈50%) and clearance ↓ (\~50%) → **oral dose ↓ 4–5×; IV ↓ \~2×**.&#x20;
* **Paracetamol**: standard 4 g/day, but conservative practice in cirrhosis uses **2–3 g/day** due to glutathione reserve/CYP2E1 considerations.&#x20;

**Scores & tests caveat:** **Child-Pugh/MELD** and routine LFTs **do not reliably predict metabolic function** or first-pass impact.&#x20;

---

# Key Concepts Checklist (copy-paste)

## Foundational Patterns

* Hepatitis (acute vs chronic), Steatosis (macro vs microvesicular), Cholestasis (pre-, intra-, post-hepatic).&#x20;

## Core Non-Neoplastic Conditions

* Viral hepatitis (HBV/HCV/HAV/HEV): patterns & serology; **HBV ground-glass**, **HCV lymphoid aggregates**.&#x20;
* Autoimmune hepatitis (plasma cells, rosettes).&#x20;
* **MAFLD/MASH** histology & risks.&#x20;
* Alcoholic hepatitis (Mallory’s hyaline).&#x20;
* **PBC** stages & AMA; **PSC** onion-skin fibrosis.&#x20;
* EHBO → bile lakes, ascending cholangitis.&#x20;
* Inherited: haemochromatosis (iron), A1AT, Wilson.&#x20;

## Neoplasms

* **HCC** risks (HBV/HCV, alcohol, aflatoxin, haemochromatosis) & vascular invasion. &#x20;
* **Cholangiocarcinoma** associations (PSC, flukes) & desmoplastic adenocarcinoma.&#x20;
* **Metastases** = commonest liver malignancy.&#x20;
* **Hepatocellular adenoma** (OCPs, rupture risk, β-catenin subtype → higher HCC risk). &#x20;
* **PDAC** risks (smoking, PanIN), perineural spread; Whipple vs distal pancreatectomy. &#x20;
* **Cystic neoplasms** (MCN/IPMN/IOPN): prognosis excellent if non-invasive; resect high-risk.&#x20;
* **Pan-NEN**: NET (G1–3) vs NEC; tail-predilection.&#x20;

## Pharmacology in Liver Disease

* **High vs low extraction**: predict effects of flow vs capacity changes.&#x20;
* **Cirrhosis PK/PD**: ↑ bioavailability (shunt), ↓ clearance (enzymes), ↑ free drug (hypoalbuminaemia), ↑ Vd (ascites), ↑ CNS sensitivity.&#x20;
* **Named examples**: diazepam→prefer lorazepam; verapamil big oral dose reduction; paracetamol conservative limit.  &#x20;

---

# Rapid “Plus-Tier” Focus (weighted by slide time)

### **3+ Detail** (master these)

* **Hepatitis spectrum** (acute/chronic + patterns, serology, histo hallmarks). &#x20;
* **MAFLD/MASH** morphology and risk factors.&#x20;
* **PBC / PSC** distinguishing features.&#x20;
* **HCC** (risks, pathology, management). &#x20;
* **PDAC** (risks, PanIN, spread, treatment). &#x20;
* **Cirrhosis pharmacology principles** (extraction ratios, examples). &#x20;

### **2+ Detail**

* **Alcohol-related liver disease** (Mallory’s, neutrophils).&#x20;
* **Hepatic metastases** basics.&#x20;
* **Hepatocellular adenoma** subtypes/risks.&#x20;
* **Pan-NEN** grading and concept.&#x20;

### **1+ Detail**

* **Acute liver failure** (recognise progression).&#x20;
* **Hepatoblastoma** recognition.&#x20;

---

## “While-You-Study” Prompts (fill-as-you-go)

* **Pattern ID:** For each case, label **hepatitis/steatosis/cholestasis** and 1 line of evidence.&#x20;
* **Progression risk:** Does this condition progress to **cirrhosis/HCC**? Why? (e.g., HBV/HCV, MASH).&#x20;
* **Serology set:** Which serologies would you order (virus/autoimmune/iron)?&#x20;
* **HPB tumour ID:** Primary vs **metastasis**; biliary vs hepatocellular clues.&#x20;
* **Drug choice tweak:** If **cirrhosis** is present, would you **avoid/swap/reduce**? (e.g., diazepam→lorazepam).&#x20;

---

If you’d like, I can turn this into a printable **one-page cram sheet** or generate **Anki cards** from the “Key Concepts Checklist.”